LP
NBIX icon

LMR Partners’s Neurocrine Biosciences NBIX Stock Holding History

LMR Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-133,400
Closed -$15.4M – 1469
2024
Q3 		$15.4M Sell
133,400
-78,400
-37% -$10.7M 0.12% 140
2024
Q2 		$29.2M Buy
211,800
+50,300
+31% +$6.9M 0.25% 79
2024
Q1 		$22.3M Buy
+161,500
New +$22.1M 0.23% 94

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's NBIX Position: Q1 2026 in Review

LMR Partners opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 55,545 shares worth $7.32M. The stake represents 0.02% of the portfolio and ranks #524 among its holdings. This is a return to the name: LMR Partners previously reported a position in NBIX as recently as Q3 2024.

LMR Partners first reported a position in NBIX in Q2 2016 and has held it in 12 quarters since. The position peaked at $10.1M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • LMR Partners held 55,545 shares of Neurocrine Biosciences worth $7.32M as of Q1 2026.
  • Neurocrine Biosciences was a new LMR Partners position in Q1 2026.
  • Neurocrine Biosciences made up 0.02% of LMR Partners's portfolio in Q1 2026, its #524 holding.
  • LMR Partners first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 12 quarters since.
  • LMR Partners's Neurocrine Biosciences position peaked at $10.1M in Q3 2018.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.